Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 1/2008

01.08.2008

Role of mean platelet volume in triagging acute coronary syndromes

verfasst von: Mehmet Birhan Yilmaz, Gokhan Cihan, Yesim Guray, Umit Guray, Halil L. Kisacik, Hatice Sasmaz, Sule Korkmaz

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Background: Acute coronary syndromes, characterized by the rupture of unstable plaque and the subsequent thrombotic process involving platelets, have been increasing in relative frequency. The central role of platelet activation has long been noticed in this pathophysiology; hence, many therapies have been directed against it. In this study, we have aimed to search prospectively the value of mean platelet volume (MPV), which is a simple and accurate measure of the functional status of platelets, in patients hospitalized with diagnosis of acute coronary syndromes (ACS). Materials and methods: A total of 216 consecutive patients (156 male, 60 female) hospitalized with the diagnosis of non-ST segment elevation (NSTE) ACS within the first 24 h of their chest pain were enrolled. One hundred and twenty patients, matched according to sex and age, with stable coronary heart disease (CHD) (85 male, 35 female) were enrolled as a control group. Patients were classified into two group: those with unstable angina (USAP, n = 105) and those with non-ST segment elevation myocardial infarction (NSTEMI, n = 111). Results: MPVs were 10.4 ± 0.6 fL, 10 ± 0.7 fL, 8.9 ± 0.7 fL consecutively for NSTEMI, USAP and stable CHD with significant differences. Patients with ischemic attacks in the first day of hospitalization accompanied by >0.05 mV ST segment shift had significantly higher MPV compared to those without such attacks (P = 0.001). Multivariable logistic regression analysis yielded that MPV (P = 0.016), platelet count (P < 0.001), and the presence of >0.05 mV ST segment depression at admission (P = 0.002) were independent predictors of development of NSTEMI in patients presenting with NSTE ACS. Conclusion: In patients presenting with NSTE ACS, higher MPV, though there are overlaps among subgroups, indicates not only more risk of having NSTEMI but also ischemic complications.
Literatur
1.
Zurück zum Zitat Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE 3rd, Steward DE, Theroux P, Gibbons RJ, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Smith SC Jr (2002) American College of Cardiology; American Heart Association. Committee on the Management of Patients with Unstable Angina. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction–summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol. 40(7):1366–1374 Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE 3rd, Steward DE, Theroux P, Gibbons RJ, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Smith SC Jr (2002) American College of Cardiology; American Heart Association. Committee on the Management of Patients with Unstable Angina. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction–summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol. 40(7):1366–1374
2.
Zurück zum Zitat Fitzgerald DJ, Roy L, Catella F, Fitzgerald A (1986) Platelet activation in unstable coronary disease. N Eng J Med 315:983–989CrossRef Fitzgerald DJ, Roy L, Catella F, Fitzgerald A (1986) Platelet activation in unstable coronary disease. N Eng J Med 315:983–989CrossRef
3.
Zurück zum Zitat Lewis HD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE 3rd, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H (1983) Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 309:396–403PubMedCrossRef Lewis HD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE 3rd, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H (1983) Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 309:396–403PubMedCrossRef
4.
Zurück zum Zitat Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, Califf RM, Navetta FI, Willerson JT, Chandra NC, Guerci AD, Ferguson JJ, Harrington RA, Lincoff AM, Yakubov SJ, Bray PF, Bahr RD, Wolfe CL, Yock PG, Anderson HV, Nygaard TW, Mason SJ, Effron MB, Fatterpacker A, Raskin S, Smith J, Brashears L, Gottdiener P, du Mee C, Kitt MM, Gerstenblith G (1996) Effects of Integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation 94:2083–2089PubMed Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, Califf RM, Navetta FI, Willerson JT, Chandra NC, Guerci AD, Ferguson JJ, Harrington RA, Lincoff AM, Yakubov SJ, Bray PF, Bahr RD, Wolfe CL, Yock PG, Anderson HV, Nygaard TW, Mason SJ, Effron MB, Fatterpacker A, Raskin S, Smith J, Brashears L, Gottdiener P, du Mee C, Kitt MM, Gerstenblith G (1996) Effects of Integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation 94:2083–2089PubMed
5.
Zurück zum Zitat Karpatkin S (1969) Heterogeneity of human platelets. II. Functional evidence suggestive of young and old platelets. J Clin Invest 48:1083–1087PubMedCrossRef Karpatkin S (1969) Heterogeneity of human platelets. II. Functional evidence suggestive of young and old platelets. J Clin Invest 48:1083–1087PubMedCrossRef
6.
Zurück zum Zitat Martin JF, Bath PMW, Burr ML (1991) Influence of platelet size on outcome after myocardial infarction. Lancet 338:1409–1411PubMedCrossRef Martin JF, Bath PMW, Burr ML (1991) Influence of platelet size on outcome after myocardial infarction. Lancet 338:1409–1411PubMedCrossRef
7.
Zurück zum Zitat Davies MJ, Thomas A (1984) Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death. N Engl J Med 310:1137–1140PubMedCrossRef Davies MJ, Thomas A (1984) Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death. N Engl J Med 310:1137–1140PubMedCrossRef
8.
Zurück zum Zitat Karpatkin S (1978) Heterogeneity of human platelets. VI. Correlation of platelet function with platelet volume. Blood 51:307–316PubMed Karpatkin S (1978) Heterogeneity of human platelets. VI. Correlation of platelet function with platelet volume. Blood 51:307–316PubMed
9.
Zurück zum Zitat Levin J, Bessman JD (1983) The inverse relationship between platelet volume and platelet number. J Lab Clin Med 101:295–307PubMed Levin J, Bessman JD (1983) The inverse relationship between platelet volume and platelet number. J Lab Clin Med 101:295–307PubMed
10.
Zurück zum Zitat Thompson CB, Jakubowski JA (1988) The pathophysiology and clinical relevance of platelet heterogeneity. Blood 72:1–8PubMed Thompson CB, Jakubowski JA (1988) The pathophysiology and clinical relevance of platelet heterogeneity. Blood 72:1–8PubMed
11.
Zurück zum Zitat Martin JF (1990) Platelet heterogeneity in vascular disease. In: Martin JF, Trowbridge EA (eds) Platelet heterogeneity: biology and pathology. Springer-Verlag, London, pp 205–226 Martin JF (1990) Platelet heterogeneity in vascular disease. In: Martin JF, Trowbridge EA (eds) Platelet heterogeneity: biology and pathology. Springer-Verlag, London, pp 205–226
12.
Zurück zum Zitat Karpatkin S, Strick N (1972) Heterogeneity of human platelets. V. Differences in glycolytic and related enzymes with possible relation to platelet age. J Clin Invest 51:1235–1243PubMedCrossRef Karpatkin S, Strick N (1972) Heterogeneity of human platelets. V. Differences in glycolytic and related enzymes with possible relation to platelet age. J Clin Invest 51:1235–1243PubMedCrossRef
13.
Zurück zum Zitat Karpatkin S (1969) Heterogeneity of human platelets. I. Metabolic and kinetic evidence suggestive of young and old platelets. J Clin Invest 48:1073–1082PubMedCrossRef Karpatkin S (1969) Heterogeneity of human platelets. I. Metabolic and kinetic evidence suggestive of young and old platelets. J Clin Invest 48:1073–1082PubMedCrossRef
14.
Zurück zum Zitat Martin JF, Trowbridge EA, Salmon GL, Plumb J (1983) The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res 32:443–460PubMedCrossRef Martin JF, Trowbridge EA, Salmon GL, Plumb J (1983) The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res 32:443–460PubMedCrossRef
15.
Zurück zum Zitat Jakubowski JA, Thompson CB, Vaillancourt R, Valeri CR, Deykin D (1983) Arachidonic acid metabolism by platelets of differing size. Br J Haematol 53:503–511PubMedCrossRef Jakubowski JA, Thompson CB, Vaillancourt R, Valeri CR, Deykin D (1983) Arachidonic acid metabolism by platelets of differing size. Br J Haematol 53:503–511PubMedCrossRef
16.
Zurück zum Zitat Tschoepe D, Roesen P, Kaufmann L, Schauseil S, Kehrel B, Ostermann A, Gries FA (1990) Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest 20:166–170PubMed Tschoepe D, Roesen P, Kaufmann L, Schauseil S, Kehrel B, Ostermann A, Gries FA (1990) Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest 20:166–170PubMed
17.
Zurück zum Zitat Giles H, Smith REA, Martin JF (1994) Platelet glycoprotein IIb–IIIa and size are increased in acute myocardial infarction. Eur J Clin Invest 24:69–72PubMedCrossRef Giles H, Smith REA, Martin JF (1994) Platelet glycoprotein IIb–IIIa and size are increased in acute myocardial infarction. Eur J Clin Invest 24:69–72PubMedCrossRef
18.
Zurück zum Zitat Heath MF, Evans RJ, Poole AW, Hayes LJ, McEvoy RJ, Littler RM (1994) The effects of aspirin and paracetamol on the aggregation of equine blood platelets. J Vet Pharmacol Ther 17(5):374–378PubMedCrossRef Heath MF, Evans RJ, Poole AW, Hayes LJ, McEvoy RJ, Littler RM (1994) The effects of aspirin and paracetamol on the aggregation of equine blood platelets. J Vet Pharmacol Ther 17(5):374–378PubMedCrossRef
19.
Zurück zum Zitat Thompson CB, Jakubowski JA, Quinn PG, Deykin D, Valeri CR (1983) Platelet size as a determinant of platelet function. J Lab Clin Med 101:205–213PubMed Thompson CB, Jakubowski JA, Quinn PG, Deykin D, Valeri CR (1983) Platelet size as a determinant of platelet function. J Lab Clin Med 101:205–213PubMed
20.
Zurück zum Zitat Thompson CB, Eaton KA, Princiotta SM, Rushin CA, Valeri CR (1982) Size dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity and function. Br J Haematol 50:509–519PubMedCrossRef Thompson CB, Eaton KA, Princiotta SM, Rushin CA, Valeri CR (1982) Size dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity and function. Br J Haematol 50:509–519PubMedCrossRef
21.
Zurück zum Zitat Kishk YT, Trowbridge EA, Martin JF (1985) Platelet volume subpopulations in acute myocardial infarction: an investigation of their homogeneity for smoking, infarct size and site. Clin Sci 68:419–425PubMed Kishk YT, Trowbridge EA, Martin JF (1985) Platelet volume subpopulations in acute myocardial infarction: an investigation of their homogeneity for smoking, infarct size and site. Clin Sci 68:419–425PubMed
22.
Zurück zum Zitat Pizzulli L, Yang A, Martin JF, Lüderitz B (1998) Changes in platelet size and count in unstable angina compared to stable angina or non cardiac chest pain. Eur Heart J 19:80–84PubMedCrossRef Pizzulli L, Yang A, Martin JF, Lüderitz B (1998) Changes in platelet size and count in unstable angina compared to stable angina or non cardiac chest pain. Eur Heart J 19:80–84PubMedCrossRef
23.
Zurück zum Zitat Thompson CB, Love DG, Quinn PG, Valeri CR (1983) Platelet size does not correlate with platelet age. Blood 62:487–494PubMed Thompson CB, Love DG, Quinn PG, Valeri CR (1983) Platelet size does not correlate with platelet age. Blood 62:487–494PubMed
24.
Zurück zum Zitat Martin JF, Penington DG (1983) The relationship between the age and density of circulating 51-Cr labelled platelets in the sub-human primate. Thromb Res 30:157–164PubMedCrossRef Martin JF, Penington DG (1983) The relationship between the age and density of circulating 51-Cr labelled platelets in the sub-human primate. Thromb Res 30:157–164PubMedCrossRef
25.
Zurück zum Zitat Yang A, Pizzulli L, Luderitz B (2006) Mean platelet volume as marker of restenosis after percutaneous transluminal coronary angioplasty in patients with stable and unstable angina pectoris. Thromb Res 117(4):371–377PubMedCrossRef Yang A, Pizzulli L, Luderitz B (2006) Mean platelet volume as marker of restenosis after percutaneous transluminal coronary angioplasty in patients with stable and unstable angina pectoris. Thromb Res 117(4):371–377PubMedCrossRef
26.
Zurück zum Zitat Alexander JH, Harrington RA, Tuttle RH, Berdan LG, Lincoff AM, Deckers JW, Simoons ML, Guerci A, Hochman JS, Wilcox RG, Kitt MM, Eisenberg PR, Califf RM, Topol EJ, Karsh K, Ruzyllo W, Stepinska J, Widimsky P, Boland JB, Armstrong PW (1999) Prior aspirin use predicts worse outcomes in patients with non-ST elevation acute coronary syndromes. Am J Cardiol 83:1147–1151PubMedCrossRef Alexander JH, Harrington RA, Tuttle RH, Berdan LG, Lincoff AM, Deckers JW, Simoons ML, Guerci A, Hochman JS, Wilcox RG, Kitt MM, Eisenberg PR, Califf RM, Topol EJ, Karsh K, Ruzyllo W, Stepinska J, Widimsky P, Boland JB, Armstrong PW (1999) Prior aspirin use predicts worse outcomes in patients with non-ST elevation acute coronary syndromes. Am J Cardiol 83:1147–1151PubMedCrossRef
27.
Zurück zum Zitat Parise LV, Venton DL, Le Breton GC (1982) Thromboxane A2/prostaglandin H2 directly stimulates platelet shape change independent of secreted ADP. J Pharmacol Exp Ther 222(1):276–281PubMed Parise LV, Venton DL, Le Breton GC (1982) Thromboxane A2/prostaglandin H2 directly stimulates platelet shape change independent of secreted ADP. J Pharmacol Exp Ther 222(1):276–281PubMed
Metadaten
Titel
Role of mean platelet volume in triagging acute coronary syndromes
verfasst von
Mehmet Birhan Yilmaz
Gokhan Cihan
Yesim Guray
Umit Guray
Halil L. Kisacik
Hatice Sasmaz
Sule Korkmaz
Publikationsdatum
01.08.2008
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 1/2008
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-007-0078-9

Weitere Artikel der Ausgabe 1/2008

Journal of Thrombosis and Thrombolysis 1/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.